🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re grateful for our incredible employees, trusted partners, and dedicated collaborators. Together, we make a difference every day—for the patients who inspire our work. Wishing you all a warm and happy Thanksgiving! 🦃🍂 #BeAdaptive

A record-breaking 65 presentations will feature MRD testing with clonoSEQ at #ASH2024. Learn more: adaptivebio.tech/lhy clonoSEQ is FDA-cleared to assess MRD in MM, CLL and ALL; CLIA-validated as an LDT. For sample types & test limitations: rb.gy/8tju9y

Check out the latest new MRD evidence at #ASH24: adaptivebio.tech/amg clonoSEQ is FDA-cleared to assess MRD in MM, CLL and ALL; CLIA-validated as an LDT. For sample types & test limitations: rb.gy/8tju9y

Warm holiday wishes from all of us at Adaptive!

Thanks to our Adapters for driving important progress this year and contributing to a workplace where collaboration and purpose thrive. Looking forward to what’s to come in 2025!

Thanks to our Adapters for driving important progress this year, and contributing to a workplace where collaboration and purpose thrive. Looking forward to what’s to come in 2025! #BeAdaptive

CEO Chad Robins will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 5:15 p.m. PT. Access to the live and archived webcast of the presentation will be available on the “Investors” section of the Adaptive website. adaptivebio.tech/qyn

Adaptive is proud to score 80/100 on HRC’s 2025 Corporate Equality Index. This reflects our ongoing commitment to an inclusive workplace for LGBTQ+ team members. Learn more: bit.ly/4271Jdr

This World Cancer Day, hear from Jim, a patient with DLBCL and an avid cyclist, about how MRD testing results empowered him to live a normal life. #WorldCancerDay #Oncology #MRDTesting #UnitedbyUnique bit.ly/4gsqMvf

Last week, our MRD team came together in St. Petersburg, Florida for our annual national meeting. It was an inspiring week of collaboration, innovation, and building momentum for 2025. Together, we’re driving advancements and shaping the future of MRD in lymphoid cancers!

Happy International Women’s Day! Today, we celebrate the women of Adaptive for their vision, leadership, and passion. You are vital to our mission of powering immune medicine and making a difference for patients worldwide. #IWD2025 #AccelerateAction

Adaptive's Sharon Benzeno, PhD (Sharon Benzeno) will speak at the #IO360Summit (March 24-26). She’ll share how AI is driving R&D in immuno-oncology and join a panel on "Navigating IO drug development for biotechs in a saturated field." Don’t miss it! #ImmunoOncology #LifeSciences

Panelists from the Women at Adaptive Employee Resource Group Career Chat on ‘Building Trust and Influence’ share whom and what inspires them during Women’s History Month. #WomensHistoryMonth

Panelists from the Women at Adaptive Employee Resource Group Career Chat on ‘Building Trust and Influence’ share whom and what inspires them during Women’s History Month. #WomensHistoryMonth

Panelists from the Women at Adaptive Employee Resource Group Career Chat on ‘Building Trust and Influence’ share whom and what inspires them during Women’s History Month. #WomensHistoryMonth

Panelists from the Women at Adaptive Employee Resource Group Career Chat on ‘Building Trust and Influence’ share whom and what inspires them during Women’s History Month. #WomensHistoryMonth

Happy Medical Laboratory Professionals Week! We proudly recognize the dedication and skill of our clinical lab staff and scientists. Your work is essential to providing accurate and timely results to inform patient care, and we’re deeply grateful for all you do. #LabWeek2025

Your clonoSEQ #MRD reports are now available through MyChart, an online portal where you can view new and historical test results. Learn more: clonoseq.com/get-my-clonose… clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: rb.gy/8tju9y

MRD is playing a central role in clinical management and drug development for lymphoid cancers. Read about the 30 abstracts using clonoSEQ MRD assessment being presented at #ASCO2025 and #EHA2025: adaptivebio.tech/rtv

We’re excited to join the European hematology community for #EHA2025 in Milan, Italy to discuss the latest data impacting the treatment landscape. Visit us at Booth F.01!